%0 Journal Article
%T 阿帕替尼在肝细胞癌治疗中的临床研究进展<br>Clinical Research Progress of Apatinib in the Treatment of Hepatocellular Carcinoma
%A 冯源
%A 涂兵
%A 李思朋
%J Advances in Clinical Medicine
%P 6195-6200
%@ 2161-8720
%D 2021
%I Hans Publishing
%R 10.12677/ACM.2021.1112919
%X 肝细胞癌是临床常见的恶性肿瘤，严重影响人民的身体健康，因其发病隐匿，大多数患者确诊时已是中晚期，丧失手术机会，靶向药物治疗作为中晚期肝细胞癌的主要治疗策略，已广泛应用于临床。以往用于治疗肝细胞癌的一线靶向药物有索拉菲尼、仑伐替尼，阿帕替尼作为新型的口服小分子抗血管生成药物，近年来在对肝细胞癌的治疗中取得了较好的疗效，成为了治疗肝细胞癌的二线治疗。本文就阿帕替尼在肝细胞癌的作用机制、临床研究进展、药物不良反应等进行综述。<br />
Hepatocellular carcinoma (HCC) is a common cancer in clinic, and HCC is one of the diseases that threaten the health and life of human. Because of its insidious onset, most patients are in the middle and late stages when they are diagnosed, and they have lost the opportunity for surgery. Targeted therapy is the main treatment strategy for advanced HCC in clinical practice. Sorafenib and lenvatinib are once the first-line therapeutic agent for HCC patients. In recent years, apatinib, which is an orally novel small-molecule anti-angiogenesis inhibitor, has shown good efficacy and has become the second-line drug in the treatment of HCC. This article reviews the mechanism, current research progress and adverse drug reaction of apatinib in HCC.
%K 阿帕替尼，肝细胞癌，临床研究进展，抗血管生成<br>Apatinib
%K Hepatocellular Carcinoma (HCC)
%K Clinical Research Progress
%K Anti-Angiogenesis
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=47683